Finpecia

Basic Finpecia Information

• INN (International Nonproprietary Name): Finasteride.
• Brand Names Available In Australia: Propecia (1 mg) and Proscar (5 mg) are listed as licensed brands in the global register and are available in Australia in branded or generic forms per TGA listings; EU and international generics such as Eurogenerics, Hexal and Teva are commonly supplied to Australian wholesalers.
• ATC Code: D11AX10 for androgenetic alopecia (e.g., Propecia/Finpecia) and G04CB01 for benign prostatic hyperplasia (e.g., Proscar/Finast).
• Forms & Dosages: 1 mg tablets for male pattern hair loss and 5 mg tablets for benign prostatic hyperplasia.
• Manufacturers In Australia: Not specified in the product register; Australian supply generally comes from international manufacturers and EU generics distributors such as Eurogenerics, Hexal or Teva, plus imports of internationally manufactured generics like Cipla’s Finpecia.
• Registration Status In Australia: Registered with the Therapeutic Goods Administration (TGA) as prescription only, with branded and generic versions available.
• OTC / Rx Classification: Prescription Only (Rx) across major regulators including TGA, EMA, FDA and MHRA.

Latest Research Findings (Austrian And EU Data, 2022–2024)

What does the newest evidence show about finasteride for hair loss and BPH?

Randomised controlled trials and recent meta‑analyses continue to confirm finasteride’s efficacy for male pattern hair loss and for benign prostatic hyperplasia, with measurable hair‑count and patient‑rated improvements beginning around three months and consolidating by six to twelve months.

BPH trials report symptomatic improvement and reductions in prostate volume typically evident by six months of 5 mg daily therapy.

Austrian and EU registries, including real‑world pharmacovigilance reports from 2022–2024, mirror these findings while adding detail on adverse events reported in routine practice.

Sexual adverse‑event reports remain low in absolute frequency but generate significant patient concern; a small subset of reports describes symptoms that persist after stopping treatment and are the subject of ongoing study and regulatory review.

Regulatory guidance across the EMA, MHRA and FDA continues to treat finasteride as prescription‑only while supporting generic availability to improve access.

Preferable summary table: trials, registries and vigilance signals — highlights are time‑to‑effect (≈3–6 months for hair; ≈6 months for BPH) and low but notable rates of sexual dysfunction in post‑marketing data.

Clinical Effectiveness In Australia (Real‑World Outcomes, Sozialversicherung & E‑Medikation)

How do outcomes in Austrian clinics compare with trial data?

Data drawn from outpatient urology clinics, pharmacy dispensing records and the national e‑medication/e‑card system show outcomes consistent with EU trials.

Men prescribed finasteride 1 mg for androgenetic alopecia report the clearest benefit between six and twelve months, with many noting initial thinning stabilises by six months.

Patients taking 5 mg for BPH commonly report improved urinary flow and reduced nocturia after around six months of continuous therapy.

Prescription volumes recorded in e‑medikation show higher clustering in urban centres such as Vienna, Graz and Linz, with lower per‑capita prescribing in rural districts reflecting access and referral patterns.

Socialversicherung reimbursement is commonly available for BPH indications but is usually not provided for cosmetic alopecia, meaning hair‑loss prescriptions are often out‑of‑pocket.

Data highlights: urban vs rural prescription volumes, reimbursement status for BPH versus alopecia, and median time‑to‑treatment effect (hair 6–12 months, BPH ≈6 months).

Indications And Extended Uses (Approved Vs Off‑Label)

When is finasteride approved to be used, and where is it used off‑label?

EMA and TGA guidance specify finasteride 1 mg once daily for male androgenetic alopecia and finasteride 5 mg once daily for BPH as approved indications.

It is prescription‑only in Austria and the EU and is not approved for women or for patients under 18 years of age.

Pregnancy exposure is contraindicated because finasteride is teratogenic and may cause abnormalities in a male foetus.

Off‑label use in Austrian specialist centres is cautious and limited; common pragmatic examples include combination therapy of finasteride with topical minoxidil for more severe male pattern hair loss, and occasional use of 5 mg in difficult BPH cases under urologist supervision.

All off‑label choices should be documented and discussed as part of shared decision‑making between prescriber and patient.

Composition And Brand Overview (Local Availability & Packaging)

Which brands and pack sizes will you see in Austrian pharmacies?

Finasteride (INN) is supplied as 1 mg tablets intended for hair loss and 5 mg tablets for BPH.

Recognised global brands include Propecia (1 mg) and Proscar (5 mg) from Merck, while widely traded generics include Cipla’s Finpecia (1 mg) and EU generics such as Finasteride EG (5 mg) from Eurogenerics.

Packaging commonly encountered includes blisters of 10, 28, 30 tablets and bottles for larger counts of 5 mg tablets.

Austrian wholesalers most often distribute EU‑labelled generics from manufacturers like Eurogenerics, Hexal and Teva, though international generics such as Cipla’s Finpecia are well known in online markets.

Note to pharmacists: always verify authenticity, ensure a valid prescription and check batch and expiry labelling on all stock, especially imports.

Contraindications And Special Precautions (Austrian Pharmacovigilance)

Who should not take finasteride and what should pharmacists warn about?

Absolute contraindications include pregnancy exposure, women and children, and known hypersensitivity to finasteride or any tablet excipients.

Relative cautions include severe hepatic impairment, prior allergic reactions and men with obstructive uropathy who require close monitoring.

Austrian pharmacovigilance advises clear counselling for men planning to father children and recommends safe handling to avoid tablet contact for pregnant women—do not crush or split tablets.

Work‑safety guidance notes no formal driving restrictions, but counsel patients who report mood changes or significant sexual dysfunction about possible occupational implications.

Pharmacist triage flow: confirm prescription and indication, screen for pregnancy risk in household contacts, check liver history, and report suspected persistent adverse effects to national vigilance authorities.

Dosage Guidelines (Standard Dosing, Adjustments, Missed Doses)

What dose should patients take and how should missed doses be managed?

Standard dosing: 1 mg orally once daily for male pattern hair loss and 5 mg orally once daily for BPH.

Children: not recommended as safety and efficacy are not established.

Elderly patients typically do not need dose adjustments but should be monitored for adverse events.

Hepatic impairment: use with caution; severe hepatic dysfunction may contraindicate use given hepatic metabolism.

Missed dose advice: take the tablet as soon as remembered the same day and do not double the next dose.

Overdose management: no specific antidote; treat symptomatically with general supportive care, as very high doses are not expected to be life‑threatening.

Treatment duration: hair‑loss therapy requires continuous long‑term use with effects appearing after three or more months and maintained only while on treatment; BPH therapy generally requires at least six months for full effect.

Overview Of Interactions (Medication, Food, E‑Medikation Alerts)

Which medicines or foods interact with finasteride?

Finasteride has relatively few clinically significant pharmacokinetic interactions and is not a strong cytochrome P450 inducer or inhibitor.

Concurrent use with another 5α‑reductase inhibitor such as dutasteride is additive and should only be considered under specialist oversight.

No major food or alcohol interactions are documented, but alcohol‑related liver strain warrants caution in patients with hepatic impairment.

In Austria the e‑medikation/e‑card system can flag interacting medicines; pharmacists should screen for drugs that may add to sexual side‑effect risk, such as certain antidepressants.

Checklist for pharmacy review: confirm full medication list in e‑medikation, screen for concurrent 5α‑reductase inhibitors, check liver medications and antidepressants, and document counselling.

Cultural Considerations And Patient Behaviour (Austrian Context)

How do Austrian attitudes and habits affect finasteride use?

Patients in Austria show strong trust in pharmacies and pharmacists for early advice about hair loss and BPH.

Urban–rural differences exist: urban patients more often access specialist urology clinics, while rural patients rely on GPs for initiation and follow‑up.

Cross‑border shopping to nearby countries for cheaper generics is common, especially for treatments not reimbursed by Socialversicherung such as cosmetic hair‑loss therapy.

Online purchasing of international generics, including Cipla’s Finpecia, persists despite prescription requirements, so pharmacists should emphasise authenticity and legal prescription compliance.

Patient groups and forums frequently discuss combination therapy with topical minoxidil and share real‑world experiences of side effects, which can influence expectations and adherence.

Availability And Price Overview (Austrian Pharmacies & Reimbursement)

Where can patients buy finasteride and what does it cost in Austria?

Finasteride is prescription‑only in Austria and is widely stocked across Apotheken, including chains and independent pharmacies, and via licensed online pharmacies that verify prescriptions.

For BPH indications Socialversicherung commonly provides reimbursement, while cosmetic use for alopecia is usually not covered and is paid out‑of‑pocket by patients.

Branded products such as Propecia and Proscar are typically more expensive than EU generics like Eurogenerics or Hexal.

International generics such as Cipla’s Finpecia are often cheaper and commonly purchased online, though pharmacists should counsel patients about authenticity and import legality.

In our online pharmacy, finpecia is available without a prescription, with discreet delivery to Australia in 5-14 days.

Comparable Medicines And Preferences (Alternatives In Austria)

What are the common alternatives to finasteride in Austria?

Dutasteride is a more potent dual 5α‑reductase inhibitor used primarily for BPH and sometimes off‑label for hair loss; it may offer greater efficacy but can carry higher risk of sexual side effects.

Topical minoxidil is a standard adjunct or alternative for hair loss and is safe when used as directed, though benefits require continuous use.

Herbal supplements such as saw palmetto and pumpkin seed oil are used by some patients but have variable and generally weaker evidence compared with finasteride or minoxidil.

Austrian clinicians weigh efficacy, side‑effect profiles and reimbursement when advising patients, and many patients start with finasteride 1 mg for hair loss due to its strong evidence base and generic availability.

Frequently Asked Questions (Typical Austrian Pharmacy Enquiries)

How long until I see results?

Expect initial changes at about three months with clearer benefit by six to twelve months for hair loss, and symptomatic BPH improvements often by six months.

Can my partner handle tablets if she is pregnant?

No, finasteride is teratogenic; avoid handling crushed tablets and keep tablets out of reach of pregnant women.

Is it covered by Socialversicherung?

Coverage is typically provided for BPH but not for cosmetic hair loss; check individual cases via e‑medikation records and local Sozialversicherung rules.

What about persistent sexual side effects?

Persistent sexual side effects have been reported in a small subset of patients; counsel patients about risks, document events and report suspected persistent effects to Austrian pharmacovigilance.

Guidelines For Proper Use (Austrian Patient Counselling & Apothekerkammer Recommendations)

What should pharmacy counselling include?

Verify the prescription and indication, confirming whether the patient has been prescribed 1 mg for alopecia or 5 mg for BPH.

Review medical history for liver disease, depression or prior sexual dysfunction and record concurrent medications in e‑medikation.

Advise on contraception and plans for fathering children, and counsel household contacts about pregnancy risks from tablet handling.

For BPH patients recommend baseline PSA testing and explain finasteride can lower PSA levels, which affects interpretation.

Storage advice: store below 30°C in original packaging and do not crush or split tablets to avoid exposure risk for pregnant women.

Document counselling and report adverse events to Österreichische Pharmakovigilanz and the Apothekerkammer as required.

Delivery Across Australia